Daniel Stover, MD, FASCO
@stoverlab.bsky.social
Breast cancer physician-scientist | Clinical computational oncology
@OSUCCC_James | Vice Chair, @Alliance_org Breast Cmte | Views own | http://u.osu.edu/StoverLab & https://u.osu.edu/bctrp
@OSUCCC_James | Vice Chair, @Alliance_org Breast Cmte | Views own | http://u.osu.edu/StoverLab & https://u.osu.edu/bctrp
Dr. Leah @pyterlab.bsky.social is the 1st @osucccjames.bsky.social presenter at Great Lakes Breast Cancer Symposium 2025!
Thanks @upmchillmancc.bsky.social for hosting!
Thanks @upmchillmancc.bsky.social for hosting!
August 24, 2025 at 7:17 PM
Dr. Leah @pyterlab.bsky.social is the 1st @osucccjames.bsky.social presenter at Great Lakes Breast Cancer Symposium 2025!
Thanks @upmchillmancc.bsky.social for hosting!
Thanks @upmchillmancc.bsky.social for hosting!
Is liquid biopsy useful in bone-only metastatic #breastcancer?
Surprise!
✅Pts w bone-only disease are just as likely to have detectable ctDNA
✅ctDNA tumor fraction remains prognostic in bone-only setting
link.springer.com/article/10.1...
@osucccjames.bsky.social
Surprise!
✅Pts w bone-only disease are just as likely to have detectable ctDNA
✅ctDNA tumor fraction remains prognostic in bone-only setting
link.springer.com/article/10.1...
@osucccjames.bsky.social
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study - Breast Cancer Research and Treatment
Purpose Bone metastases develop in 50–70% of patients with metastatic breast cancer (MBC), with around one-third having bone as only site of distant disease (bone-only [BO]). Standard imaging is frequ...
link.springer.com
May 30, 2025 at 11:19 AM
Is liquid biopsy useful in bone-only metastatic #breastcancer?
Surprise!
✅Pts w bone-only disease are just as likely to have detectable ctDNA
✅ctDNA tumor fraction remains prognostic in bone-only setting
link.springer.com/article/10.1...
@osucccjames.bsky.social
Surprise!
✅Pts w bone-only disease are just as likely to have detectable ctDNA
✅ctDNA tumor fraction remains prognostic in bone-only setting
link.springer.com/article/10.1...
@osucccjames.bsky.social
Could not be more thankful for and proud of my parents today ❤️💯
April 5, 2025 at 9:55 PM
Could not be more thankful for and proud of my parents today ❤️💯
Reposted by Daniel Stover, MD, FASCO
Thank you to @stolaney1.bsky.social @dfcibreastonc.bsky.social for inviting me to give the J. Dirk Iglehart, M.D. Visiting Scholar Lecture at the DF/HCC Breast & Gynecologic Cancer Symposium.
Incredible science, great friends & connections - what an honor!
www.dfhcc.harvard.edu/events/dfhcc...
Incredible science, great friends & connections - what an honor!
www.dfhcc.harvard.edu/events/dfhcc...
March 28, 2025 at 9:48 PM
Thank you to @stolaney1.bsky.social @dfcibreastonc.bsky.social for inviting me to give the J. Dirk Iglehart, M.D. Visiting Scholar Lecture at the DF/HCC Breast & Gynecologic Cancer Symposium.
Incredible science, great friends & connections - what an honor!
www.dfhcc.harvard.edu/events/dfhcc...
Incredible science, great friends & connections - what an honor!
www.dfhcc.harvard.edu/events/dfhcc...
Reposted by Daniel Stover, MD, FASCO
Using Epic Signal data for 15.7K oncologists (2019->22): Mean overall EHR inbox messages ⬆️ 19%, mean overall patient-initiated messages ⬆️ 34%, & total InBasket time ⬆️ 25.4%. Total weekly EHR time by subspecialty: med onc>>gyn onc>>surg onc>>rad onc>>ped onc #burnout academic.oup.com/jnci/advance...
March 18, 2025 at 1:52 AM
Using Epic Signal data for 15.7K oncologists (2019->22): Mean overall EHR inbox messages ⬆️ 19%, mean overall patient-initiated messages ⬆️ 34%, & total InBasket time ⬆️ 25.4%. Total weekly EHR time by subspecialty: med onc>>gyn onc>>surg onc>>rad onc>>ped onc #burnout academic.oup.com/jnci/advance...
New #JITC article: T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
jitc.bmj.com/content/13/2...
jitc.bmj.com/content/13/2...
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoad...
Background Higher levels of tumor-infiltrating lymphocytes (TILs) in breast cancers are associated with increased likelihood of pathologic complete response (pCR) to chemotherapy. DNA methyltransferas...
jitc.bmj.com
March 7, 2025 at 9:46 PM
New #JITC article: T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
jitc.bmj.com/content/13/2...
jitc.bmj.com/content/13/2...
Reposted by Daniel Stover, MD, FASCO
Did you register for THE conference that covers breast cancer AND normal mammary gland development yet? The GRC Mammary Gland Biology and Neoplasia abstracts will be evaluated for short talks from trainees soon, so get your abstract in!
www.grc.org/mammary-glan...
www.grc.org/mammary-glan...
2025 Mammary Gland Biology Conference GRC
The 2025 Gordon Research Conference on Mammary Gland Biology will be held in Newry, Maine. Apply today to reserve your spot.
www.grc.org
February 27, 2025 at 10:31 PM
Did you register for THE conference that covers breast cancer AND normal mammary gland development yet? The GRC Mammary Gland Biology and Neoplasia abstracts will be evaluated for short talks from trainees soon, so get your abstract in!
www.grc.org/mammary-glan...
www.grc.org/mammary-glan...
Critical to keep shining light on the crucial issue of #financialToxicity & cancer care.
"It's so heartbreaking when someone has to do a GoFundMe to pay for their medical care or to pay for their funeral or the funeral of a loved one."
🎙️ Our #financialToxicity @ascocancer.bsky.social podcast with Drs @stage4kelly.bsky.social & @ryannipp.bsky.social is out now! Listen today:
🎙️ Our #financialToxicity @ascocancer.bsky.social podcast with Drs @stage4kelly.bsky.social & @ryannipp.bsky.social is out now! Listen today:
Debt or Dying: The JCO OP Financial Toxicity Special Issue | ASCO Publications
Host Dr. Fumiko Chino sits down with co-editor and health outcomes researcher Dr. Ryan Nipp, and contributing author Dr. Kelly Shanahan who is living with metastatic breast cancer to have a candid con...
ascopubs.org
February 13, 2025 at 9:23 PM
Critical to keep shining light on the crucial issue of #financialToxicity & cancer care.
Reposted by Daniel Stover, MD, FASCO
Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...
Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers
In this statement, ASCO encourages academic medical centers to change their policies
and expectations to enhance and promote the professional fulfillment of academic medical
oncologists. The statement...
ascopubs.org
February 12, 2025 at 2:48 AM
Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...
February 11, 2025 at 5:30 PM
Reposted by Daniel Stover, MD, FASCO
In Ohio during FY23 (2022-2023) this was the impact of NIH funding:
$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported
This reduction in NIH indirect will decimate research and limit health care advances
www.unitedformedicalresearch.org/nih-in-your-...
$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported
This reduction in NIH indirect will decimate research and limit health care advances
www.unitedformedicalresearch.org/nih-in-your-...
NIH In Your State - United For Medical Research
Select a state on the map to see the impact of NIH funding across America.
www.unitedformedicalresearch.org
February 8, 2025 at 12:20 PM
In Ohio during FY23 (2022-2023) this was the impact of NIH funding:
$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported
This reduction in NIH indirect will decimate research and limit health care advances
www.unitedformedicalresearch.org/nih-in-your-...
$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported
This reduction in NIH indirect will decimate research and limit health care advances
www.unitedformedicalresearch.org/nih-in-your-...
Oncologist burnout ⬆️14% over past 10yrs.
➡️Emotional exhaustion: 38% (2013) to 57% (2023)
➡️Top stressors: Staffing, EHR, payers
➡️Top fixes: ⬆️support, ⬇️workload
➡️What sparks joy? Talking w patients, helping pt QOL
Oncologists just want time to help patients feel better.
ascopubs.org/doi/pdf/10.1...
➡️Emotional exhaustion: 38% (2013) to 57% (2023)
➡️Top stressors: Staffing, EHR, payers
➡️Top fixes: ⬆️support, ⬇️workload
➡️What sparks joy? Talking w patients, helping pt QOL
Oncologists just want time to help patients feel better.
ascopubs.org/doi/pdf/10.1...
State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023 | JCO Oncology Advances
PURPOSERecent data suggest that the rate of burnout among oncologists has risen over time.
In addition to the negative effect of burnout on individuals, widespread burnout may
prevent the oncology wor...
ascopubs.org
February 4, 2025 at 3:41 AM
Oncologist burnout ⬆️14% over past 10yrs.
➡️Emotional exhaustion: 38% (2013) to 57% (2023)
➡️Top stressors: Staffing, EHR, payers
➡️Top fixes: ⬆️support, ⬇️workload
➡️What sparks joy? Talking w patients, helping pt QOL
Oncologists just want time to help patients feel better.
ascopubs.org/doi/pdf/10.1...
➡️Emotional exhaustion: 38% (2013) to 57% (2023)
➡️Top stressors: Staffing, EHR, payers
➡️Top fixes: ⬆️support, ⬇️workload
➡️What sparks joy? Talking w patients, helping pt QOL
Oncologists just want time to help patients feel better.
ascopubs.org/doi/pdf/10.1...
Reposted by Daniel Stover, MD, FASCO
Happy to share our retrospective study on #pneumonitis risk in patients with #breastcancer who receive #TDXd #Enhertu @stoverlab.bsky.social @osucccjames.bsky.social #bcsm
Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer - Breast Cancer Research
Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment...
breast-cancer-research.biomedcentral.com
February 3, 2025 at 11:18 PM
Happy to share our retrospective study on #pneumonitis risk in patients with #breastcancer who receive #TDXd #Enhertu @stoverlab.bsky.social @osucccjames.bsky.social #bcsm
Reposted by Daniel Stover, MD, FASCO
🎉Reunion w/ my co-fellow @jasminesukumar.bsky.social @mdanderson.bsky.social to discuss early #breastcancer adj tx w/ path germline muts on the @ascocancer.bsky.social Daily News podcast
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
ASCO Daily News: Advances in Adjuvant Therapy for High-Risk Early Breast Cancer With Germline Mutations
Dr. Jessica Sukumar and Dr. Dionisia Quiroga discuss advances in adjuvant therapy for patients with early breast cancer and BRCA1/2 mutations, including how to identify patients who should receive gen...
ascodaily.libsyn.com
February 2, 2025 at 7:44 PM
🎉Reunion w/ my co-fellow @jasminesukumar.bsky.social @mdanderson.bsky.social to discuss early #breastcancer adj tx w/ path germline muts on the @ascocancer.bsky.social Daily News podcast
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
Reposted by Daniel Stover, MD, FASCO
Amazing group of medical oncologists that I am privileged to work with every day and call friends @stoverlab.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @quirogad.bsky.social @osucccjames.bsky.social
February 1, 2025 at 9:23 PM
Amazing group of medical oncologists that I am privileged to work with every day and call friends @stoverlab.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @quirogad.bsky.social @osucccjames.bsky.social
Congratulations to so many fantastic individuals @drdonsdizon.bsky.social @drdawnhershman.bsky.social Susan Domchek, Ian Krop, and many others!
Alongside the Conquer Cancer Foundation we congratulate the recipients of our 2025 Special Awards! #ASCO25
Learn more: brnw.ch/21wQhFu
Learn more: brnw.ch/21wQhFu
January 28, 2025 at 8:15 PM
Congratulations to so many fantastic individuals @drdonsdizon.bsky.social @drdawnhershman.bsky.social Susan Domchek, Ian Krop, and many others!
Fantastic USC Keck SOM Breast Cancer Symposium with great faculty, fellow cases, and new collaborations.
Offering my support to all those here in LA impacted by the wildfire devastation.
Offering my support to all those here in LA impacted by the wildfire devastation.
January 26, 2025 at 12:32 AM
Fantastic USC Keck SOM Breast Cancer Symposium with great faculty, fellow cases, and new collaborations.
Offering my support to all those here in LA impacted by the wildfire devastation.
Offering my support to all those here in LA impacted by the wildfire devastation.
@drjbhattacharya.bsky.social - Need your leadership to provide clarity & support to re-initiate #NIH #NCI communications, study sections, & meetings. Abrupt stop with no clear path forward causing confusion.
Biomedical research is a critical engine of progress, health, and economic activity.
Biomedical research is a critical engine of progress, health, and economic activity.
January 23, 2025 at 1:19 PM
@drjbhattacharya.bsky.social - Need your leadership to provide clarity & support to re-initiate #NIH #NCI communications, study sections, & meetings. Abrupt stop with no clear path forward causing confusion.
Biomedical research is a critical engine of progress, health, and economic activity.
Biomedical research is a critical engine of progress, health, and economic activity.
Reposted by Daniel Stover, MD, FASCO
Great segment on @nbc4i.bsky.social by @stoverlab.bsky.social @osucccjames.bsky.social on the recent #ACS cancer stats www.nbc4i.com/video/annual...
Annual cancer study shows who could be diagnosed this year
Annual cancer study shows who could be diagnosed this year
www.nbc4i.com
January 23, 2025 at 1:29 AM
Great segment on @nbc4i.bsky.social by @stoverlab.bsky.social @osucccjames.bsky.social on the recent #ACS cancer stats www.nbc4i.com/video/annual...
Kim Rathmell to step down as NCI Director January 20. Hope that we can benefit from her leadership at the NCI again in the future.
January 17, 2025 at 7:01 PM
Kim Rathmell to step down as NCI Director January 20. Hope that we can benefit from her leadership at the NCI again in the future.
Reposted by Daniel Stover, MD, FASCO
🚨 The #FinancialToxicity special issue of JCO OP is LIVE today! 🚨
We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap!
ascopubs.org/toc/op/21/1
We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap!
ascopubs.org/toc/op/21/1
JCO Oncology Practice: Vol 21, No 1
ascopubs.org
January 11, 2025 at 12:31 AM
🚨 The #FinancialToxicity special issue of JCO OP is LIVE today! 🚨
We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap!
ascopubs.org/toc/op/21/1
We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap!
ascopubs.org/toc/op/21/1
Reposted by Daniel Stover, MD, FASCO
Thank you @ascocancer.bsky.social for devoting an entire issue of JCO OP to the topic of #FinancialToxicity and thank you to @fumikochino.bsky.social @ryannipp.bsky.social for inviting me to 🖊️ a piece for this, on my experience with financial toxicity as someone with privilege and savings.
🚨 The #FinancialToxicity special issue of JCO OP is LIVE today! 🚨
We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap!
ascopubs.org/toc/op/21/1
We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap!
ascopubs.org/toc/op/21/1
JCO Oncology Practice: Vol 21, No 1
ascopubs.org
January 11, 2025 at 6:27 PM
Thank you @ascocancer.bsky.social for devoting an entire issue of JCO OP to the topic of #FinancialToxicity and thank you to @fumikochino.bsky.social @ryannipp.bsky.social for inviting me to 🖊️ a piece for this, on my experience with financial toxicity as someone with privilege and savings.
If physician-scientists were 'in it for the money', we would probably choose different jobs .
🤔Incentives for research are 1) poorly delineated; 2) infrequently implemented; 3) lag clinical incentives many fold.
💰 is not the *only* incentive: research time, space, institutional support are valued
🤔Incentives for research are 1) poorly delineated; 2) infrequently implemented; 3) lag clinical incentives many fold.
💰 is not the *only* incentive: research time, space, institutional support are valued
December's most engaging article by Eva Catenaccio et al. shows that prolonged physician-scientist training postpones full salary earnings compared with MD physicians & MD-PhD physicians have a lower lifetime earning potential than MD physicians... https://insight.jci.org/articles/view/183476
January 8, 2025 at 7:40 PM
If physician-scientists were 'in it for the money', we would probably choose different jobs .
🤔Incentives for research are 1) poorly delineated; 2) infrequently implemented; 3) lag clinical incentives many fold.
💰 is not the *only* incentive: research time, space, institutional support are valued
🤔Incentives for research are 1) poorly delineated; 2) infrequently implemented; 3) lag clinical incentives many fold.
💰 is not the *only* incentive: research time, space, institutional support are valued
Welcome to Nerea Lopetegui-Lia to the @osuwexmed.bsky.social @osucccjames.bsky.social Breast Medical Oncology Team!
Very excited to have her join us from @clevelandclinic.bsky.social and can't wait to see the impact she has on breast cancer field and individual patients!
Very excited to have her join us from @clevelandclinic.bsky.social and can't wait to see the impact she has on breast cancer field and individual patients!
January 8, 2025 at 7:34 PM
Welcome to Nerea Lopetegui-Lia to the @osuwexmed.bsky.social @osucccjames.bsky.social Breast Medical Oncology Team!
Very excited to have her join us from @clevelandclinic.bsky.social and can't wait to see the impact she has on breast cancer field and individual patients!
Very excited to have her join us from @clevelandclinic.bsky.social and can't wait to see the impact she has on breast cancer field and individual patients!